CSN's Cement Unit Sale Could Exceed $2 Billion as Global Giants Circle 
How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
DEEPX Partners with Hyundai to Power Next-Gen AI Robots Ahead of IPO 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
Elon Musk's Terafab Foundry Courts Top Chipmaking Giants for AI Self-Sufficiency Push 
Daikin Industries Stock Surges 14% After Elliott Investment Management Discloses Major Stake 
Anthropic CEO Meets Trump Officials to Discuss Powerful New AI Model Mythos 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
Want to cut your energy bills? Here’s how five experts are doing it 
TSMC Posts Record Q1 Profit Fueled by AI Chip Demand 
Netflix Q2 Profit Warning Sends Shares Tumbling as Reed Hastings Exits 
Japan Opens Arms Export Floodgates: New Policy Draws Global Defense Interest 
Uber Bets Big on Autonomous Vehicles with $10 Billion Commitment 
ASML Raises 2026 Revenue Outlook as AI Chip Demand Surges 
Samsung Races to Deliver Next-Gen HBM4E Memory Samples to Nvidia 
Hermès Q1 2026 Sales Miss Expectations Amid Iran War and China Slowdown 
NiSource Signs Long-Term Energy Deals with Alphabet and Amazon to Power Indiana Data Centers 
EMERYVILLE, Calif., May 31, 2017 -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, today announced that Michael P. Smith, Executive Vice President, Chief Financial Officer & Treasurer and Secretary, will present a corporate overview at the Jefferies 2017 Global Healthcare Conference, taking place on June 6-9, 2017, in New York, NY.
Zogenix Presentation Details
| Date: | Wednesday, June 7, 2017 |
| Time: | 2:00 pm Eastern Time / 11:00 am Pacific Time |
The presentation will be webcast live and archived for 30 days on Zogenix's Investor Relations website at ir.zogenix.com.
About Zogenix
Zogenix, Inc. (Nasdaq:ZGNX) is a pharmaceutical company committed to developing and commercializing CNS therapies that address specific clinical needs for people living with orphan and other CNS disorders who need innovative treatment alternatives to improve their daily functioning.
For more information, visit www.zogenix.com.
CONTACT: Investors: Andrew McDonald Founding Partner, LifeSci Advisors LLC 646-597-6987 | [email protected]
